Do we need to change our administration practice with regard to sodium ferric gluconate complex in glucose? [10]

Nephrology Dialysis Transplantation

Volumn 20, Issue , 2005, Pages 1279-

  Bhowmik, Dipankarc ^a   Tiwari, Suresh C ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN; FERRIC GLUCONATE; GLUCOSE; IRON DEXTRAN; PLACEBO;

ANAPHYLAXIS; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; HUMAN; INCIDENCE; INDIA; LETTER; MOLECULAR WEIGHT; NEPHROLOGY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; UNITED STATES;

FERRIC COMPOUNDS; GLUCONATES; HUMANS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 20844445825     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh552     Document Type: Letter

References (4)

1. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19: 1571-1575
2. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41 [Suppl 5]: S18-S26
3. Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-1839
4. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-224